At Health Enterprise East we believe in improving healthcare through technology and innovation
Aseptuva Ltd is developing a pioneering medical device designed to combat hospital-acquired infections (HAIs) by integrating a UV-emitting component directly with central venous catheters (CVCs). Enabled by the ‘RTO Catapult Grant’ scheme from Innovate UK Business Growth, Health Tech Enterprise (HTE) collaborated with Aseptuva to deliver two complementary workstreams: an in-depth overview of NHS medical […]
Enabled by the RTO grant from UK Edge Innovate UK Business Growth, Health Tech Enterprise has collaborated with the team at Capa Valve to carry out a rigorous usability study to evaluate how intended users interacted with two versions of the Capa Valve PFS-LS-RD (Pre-Filled-Syringe, Liquid Solid, Reconstitution & Delivery) syringe. The data from the study […]
Dignity Care Founded by Laura Corcoran, Dignity Care have developed the Miscarriage Collection Cradle; a patented, Class I Medical Device designed to restore dignity , privacy, and clinical safety to the miscarriage process. Enabled by the RTO grant from UK Edge Innovate UK Business Growth, Health Tech Enterprise has collaborated with Dignity Care to develop […]
Tutti Toot Ltd is developing a novel medical device designed to address adherence challenges in Airway Clearance Techniques (ACT) for patients with chronic respiratory conditions. The Tutti Toot Trumpet is a gamified musical device that provides real-time Positive Expiratory Pressure (PEP) measurements to facilitate effective therapy. To support their commercial strategy and strengthen their value […]
FlowSync Solutions Ltd is developing a groundbreaking solution to address the critical issue of fluid management in surgical and acute care settings using a novel automated system. Flowmaster 1.0 is designed to track fluid balance in patients with precision, the device provides real-time data to prevent complications such as fluid overload and dehydration. To solidify […]
The Bedhead Tidy was developed by nurse Emma Thomson and former biomedical engineer Steve Connew at East Suffolk and North Essex NHS Foundation Trust after they were concerned with the disorganised storage of tubing and cables hung by patients’ beds causing contamination issues and avoidable additional costs. They needed a holder which was simple, easy […]
Intracoronary optical coherence tomography (OCT) is a high-resolution imaging technique that captures detailed views of the coronary arteries, enabling early diagnosis of cardiovascular disease during percutaneous coronary intervention (PCI) procedures. However, interpreting OCT data remains complex and time-consuming, making it an ideal candidate for AI innovation.
Dr John Scott Frazer, a doctor working in anaesthetics and intensive care at North West Anglia NHS Foundation Trust, has worked with Health Tech Enterprise (HTE) to develop his concept for the PediJect device, a dose adjustable prefilled medication syringe for use in children’s emergencies.
MultiplAI can now make informed, strategic decisions about their market entry and regulatory pathway. The insights provided helped the company refine their priorities and navigate the key steps required to obtain regulatory approvals.
The insights generated through Health Tech Enterprise’s research and stakeholder interviews provided Puddle Technology with independent validation of the sizeable market opportunity for their device. The resulting report confirmed the market potential for an alternative visualization tool for thoracentesis, prioritized the market focus and uncovered additional care pathways where the device could deliver significant clinical and patient benefits.
Supersense Technologies, with the support of Health Tech Enterprise, has solidified a strategic pathway to bring its pioneering remote monitoring platform to market. By leveraging invaluable market knowledge and stakeholder insights, Supersense can now focus on an optimal market sector and payer type, ensuring their development efforts are precisely aligned with market needs and redefining the future of independent living for individuals with mild dementia.
Health Tech Enterprise provided Open Medical with a SIMUL8-based waiting list simulation, enabling them to assess the mean impact of their teledermoscopy tool on patient waiting times compared to the current standard of care. This innovation showed potential to significantly reduce waiting times for skin cancer diagnoses. The comprehensive report detailed the methodology, provided key insights from the simulation outcomes, and included actionable recommendations to strengthen the evidence base for their technology.
The client had a novel product for use in patients with irritable bowel syndrome (IBS) and wished to have its product listed on the NHS Drug Tariff. To support the application, a health economic evaluation was required to demonstrate the relative cost-effectiveness of the intervention.
The team at the Electrospinning Company have developed a novel synthetic material intended for use as a graft in ophthalmic surgery. The innovative material has the potential to improve surgical outcomes in addition to being more economical that the currently used graft options.
An innovator has developed a smart referral solution. The innovation is expected to enhance efficiencies in primary and secondary care by reducing inappropriate referrals, excessive secondary care appointments, repeat GP consultations, and the administrative burden associated with triaging and managing incorrect referrals.
The innovators had developed a digital dietary education program, targeting adults with a BMI greater than 25. The program is accessible through a website and also on a mobile app, it offers structured meal plans to the user.
The innovators at Aker Health Tech have developed an automated, self-propelled robotic colonoscopy device, capable of performing a complete colonoscopy for the lower gastrointestinal tract. This innovation is projected to significantly reduce the duration of the colonoscopy procedure and the required staffing resources.
Digistain have developed an innovative tumour-grading technology that has the potential to revolutionize breast cancer treatment. This technology enables the stratification of patients based on their risk of cancer recurrence, aiming to reduce the amount of unnecessary chemotherapy treatments that are delivered.
The University of South Wales (USW) sought to commercialise a novel point of care device, developed by USW researchers, for rapidly testing COVID-19. The University was working with Public Health Wales, the University Health Board and local industry to collaboratively develop the device to meet regulatory, clinical and commercial requirements. The University required external innovation […]
The Clinical Innovators Forum is designed to provide innovators with access to specialist support and advice to help take their technology innovation projects from concept through to commercialisation.
Daiken Medical, a Japanese Medical Device Manufacturer, were seeking regulatory approval to launch one of their innovative patient-controlled analgesia (PCA) infusion pumps in Europe, with a particular focus on the UK market.
Neu Health developed a digital platform for people with Parkinson’s and dementia. The innovation facilitates patient empowerment and enables clinicians to close the care management and data gap between clinic visits, as well as reduce unnecessary journeys for both patients and healthcare professionals.
Our client developed an innovative tumour-grading technology that enables the stratification of patients based on their risk of cancer recurrence, guiding the use of chemotherapy. The client sought to understand the quantitative evidence on the reduction of carbon footprint resulting from decreased patient travel and improved logistics.
UCL Partners is a leading Academic Health Science Network that focuses on driving research and innovation to improve patient care and promote better health outcomes. In 2022, they launched the first UCL Partners Innovation Fellowship Programme, which supports NHS fellows in developing digital-based health solutions.
Lucida Medical develops software based on artificial intelligence methods (machine learning and image processing) to enable radiologists to find cancer accurately, consistently, and quickly using MRI. Innovators at Lucida Medical developed Prostate Intelligence (PI™) to support the diagnosis of prostate cancer in patients.
Professor Vincent Gnanapragasam and colleagues developed the Cambridge Prostate Biopsy Device (CamPROBE®), an innovative device to safely access the prostate using fewer incisions through the perineum instead of via the transrectal route. As such, the device reduces the risk of infection.
Innovators from the Department of Clinical Neurosciences at the University of Cambridge had developed a machine learning algorithm to predict the speed of progression of Alzheimer’s disease. This decision support tool would enable physicians to better manage their patients by assigning them to the most appropriate treatment pathway.
ONX is a non-invasive molecular test developed by UK based Cambridge Oncometrix. The test will enable risk-stratification and improve true positive rates within the diagnostic pathway for those with suspected prostate cancer. ONX will be conducted prior to multi-parametric magnetic resonance imaging scanning, a relatively new prostate cancer screening method. As a result, ONX will alleviate the burden placed on access to mpMRI scans.
Each year, around 2,800 people in the UK experience a hole in their upper gastrointestinal (GI) tract. The presence of a hole allows leakage of gastrointestinal contents into the body which quickly leads to infection – a serious medical emergency that can be fatal if not treated. LUMEVAC™ is a pioneering endoscopic surgical device to solve this problem.
Arterial lines are frequently used in intensive care units and operating theatres to facilitate beat-to-beat monitoring of blood pressure and to allow blood sampling. The Needle-Free Arterial Non-injectable Connector (NIC) is a novel device which increases the safety of patients undergoing blood sampling.
It is conservatively estimated that 4M temporary tracheostomies are performed throughout Europe and the US each year. The procedure involves making an incision on the anterior aspect of the neck, and opening a direct airway through an incision in the trachea. Tracheseal is a dedicated tracheostomy wound dressing to be used after the removal of the tracheostomy tube.
Regional anaesthesia is directed at a specific region of the body to allow a surgical operation or provide post-operative pain relief. SAFIRA makes regional anaesthesia a one person procedure, putting control in the hands of the anaesthesiologist.
Health Tech Enterprise is a trademark of Health Tech Enterprise Ltd.
© 2026 Health Tech Enterprise Ltd, St John's Innovation Centre, Cowley Road, Cambridge CB4 0WS
Email: enquiries@healthtechenterprise.co.uk Tel: +44 (0) 1223 420 252